Titan's US subsidiary Titan America released solid FY25 results, with revenue up 1.8% and adjusted EBITDA up 5.2%. Titan America anticipates low single revenue growth and a modest expansion of adjusted EBITDA margins in 2026. We remind that Titan Group will release its FY25 results tomorrow (19 March). We remind as well that Titan presented its Forward 2029 Strategic plan in November 2025, and which targets to grow EBITDA by 62% to € 1bn by 2029 on a combination of organic growth initiatives and...
In the Investor Update, dsm-firmenich showed a detailed roadmap towards the company's mid-term targets, reflecting the anticipated step-by-step improvement. On the strategic side, dsm-firmenich will, after the announced ANH divestment, fully focus on growing its current portfolio of consumer oriented businesses. We remind that the guidance of 2026 is broadly in line with our and consensus expectations (2-4% organic sales growth and c. 20% adjusted EBITDA margin). We still appreciate dsm-firmenic...
At EAU 2026, mdxhealth presented data from Oxford's ProMPT study, demonstrating that the GPS test successfully stratifies the risk of treatment failure across treatment cohorts. The results showed high six-year freedom-from-failure rates. Mdxhealth and Oxford will continue their collaboration through the recently initiated ProtecT-GPS study, with management expecting data read-outs in 2026/2027. We believe these data could support future market share gains for GPS mdx and could help expand the m...
WEB reports FY25 results below our expectations. Rental income was approximately 1.0% lower at €25.2m vs €25.5m KBCSe. The like-for-like rental growth was negative at -0.3% as a result of rent reversion and a drop in occupancy. The occupancy improved 148bps vs 1H25 but remains 112bps lower YoY. EPRA earnings were 3.0% lower than expected at €3.55 per share, -3.8% YoY. The portfolio corrections remained negative, -1.0% like-for-like, after correcting for €2.7m acquisitions and € 3.8m capitalized...
In light of TINC's FY25 results, we have updated our model and projections. In FY25, the portfolio fair value rose to €713.2m, up 39.3% from FY24-end. This is ahead of our prior expectation and reflects record investments of €225.6m combined with solid unrealised value creation. We improved our long-term growth assumptions for the Social segment, driven by the new higher growth investments. We incorporate the remaining €103.1m in contractual commitments (mostly 2026–2028) and an estimated €70.0m...
We update our model after the FY25 results and include the new guidance on the Bel Tower project and Proximus HQ into our estimates. The Proximus HQ project moved from development projects to investment properties, resulting in a higher debt ratio as we don't factor in an immediate exit. We accelerate disposals of standing assets into our model from €50.0m to €100.0m per annum to counterbalance the €565m cash drain from developments. We downgraded Nextensa from Accumulate to Hold ahead of the re...
On Tuesday, D'Ieteren reported a strong set of FY25 results, driven by an impressive performance at Belron. We were particularly encouraged by management's confirmation that the claims avoidance situation in N-A is normalising. While the outlook was somewhat softer than expected, we believe the underlying assumptions are still rather conservative and therefore see room for D'Ieteren to comfortably deliver on its guidance. Following the rollover of our model, we arrive at a new SOTP valuation of ...
In the Investor Update, dsm-firmenich showed a detailed roadmap towards the company's mid-term targets, reflecting the anticipated step-by-step improvement. On the strategic side, dsm-firmenich will, after the announced ANH divestment, fully focus on growing its current portfolio of consumer oriented businesses. We remind that the guidance of 2026 is broadly in line with our and consensus expectations (2-4% organic sales growth and c. 20% adjusted EBITDA margin). We still appreciate dsm-firmenic...
Revenues for the year come in below expectations, mainly due to the subdued start to the year. Bottom-line numbers also below expectations, but to a significant extend explained by negative FX impact, which should largely normalize going forward. While overall 2025 was a record year for HYSG, we expect solid growth into 2026 with potentially some further upside from M&A when the large cash balance is put to work. We reiterate our Buy recommendation and the €5.5 TP.
We update our model (Buy, €45 Target Price maintained) after EVS delivered another year of solid progress, supported by a clearer operational rhythm and an improved ability to convert commercial momentum into revenue. EVS has structurally shifted to a pre-production model that shortens delivery cycles and gives customers faster turnaround, while also improving internal planning stability. This shift allowed EVS to convert a significant portion of late-2025 orders within the year, supporting s...
Over a 1-year period Wereldhave had a total return of 49.0%, a 34.3% outperformance vs. the EPRA index. The timing of this initiation comes after the stock already re-rated. We expect Wereldhave to outperform the midpoint of its FY26 guidance by 3.7% and see the premium to peers as justified given the growth rate. We initiate with an Accumulate rating and €23.0 TP.
We believe that the cautious outlook at the results on 26/2 is related to new developments from the LNS acquisitions that are added to the All-Store income at low initial Occupancy and YoC%. Shurgard now expects the EPRA EPS growth to average between 6-8% over FY27-30 (10% KBCSe). Shurgard continues its UK expansion with the completion of 5 developments (LnS pipeline) and 1 from its original pipeline in FY26. These completions have an impact on its short term all-store metrics as new developmen...
Following the recent divestment announcement of ANH, dsm-firmenich presents is updated strategy & targets in an Investor Update which will take place in London today. After the ANH divestment, dsm-firmenich will focus on its consumer oriented businesses. As previously hinted at, Dsm-firmenich reiterated the mid term financial targets for organic sales growth and adjusted EBITDA margin whilst it has upped the cash conversion target from =10% to =14%. The guidance of 2026 is a bit more cautious th...
Aalberts reported FY25 results showing continued pricing discipline and improved working capital management. While Building is bottoming out, Semicon will lead the earnings recovery. In the meantime, ambitious (German) infrastructure and defence spending plans should prepare the rebound in Industry from 2027 onwards. Strengthened confidence in our forecasts and an attractive valuation underpin our upgrade to Accumulate (from Hold) with a new €39 TP (from €33).
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.